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The consistent detection and quantification of protein post-translational modifications (PTMs) 
across sample cohorts is an essential prerequisite for the functional analysis of biological 
processes. Data-independent acquisition (DIA), a bottom-up mass spectrometry based proteomic 
strategy, exemplified by SWATH-MS, provides complete precursor and fragment ion information 
of a sample and thus, in principle, the information to identify peptidoforms, the modified variants 
of a peptide. However, due to the convoluted structure of DIA data sets the confident and 
systematic identification and quantification of peptidoforms has remained challenging. Here we 
present IPF (Inference of PeptidoForms), a fully automated algorithm that uses spectral libraries to 
query, validate and quantify peptidoforms in DIA data sets. The method was developed on data 
acquired by SWATH-MS and benchmarked using a synthetic phosphopeptide reference data set 
and phosphopeptide-enriched samples. The data indicate that IPF reduced false site-localization by 
more than 7-fold in comparison to previous approaches, while recovering 85.4% of the true 
signals. IPF was applied to detect and quantify peptidoforms carrying ten different types of PTMs 
in DIA data acquired from more than 200 samples of undepleted blood plasma of a human twin 
cohort. The data approportioned, for the first time, the contribution of heritable, environmental and 
longitudinal effects on the observed quantitative variability of specific modifications in blood 
plasma of a human population.
Introduction
Proteins catalyze and control essentially all biochemical functions of a living cell. Discovery 
mass spectrometry methods have identified products from the predicted protein coding 
regions (open reading frames, ORFs) for numerous species, including the human species, to 
apparent saturation1. Yet, the number of proteoforms expressed from a particular genome by 
far exceeds the number of protein coding ORFs because a multitude of processes contribute 
to increasing proteomic diversity. Among these, post-translational modifications (PTMs) 
generate an enormous, but as yet unknown expansion of the expressed proteoforms as each 
protein contains many amino acid residues that are potentially modified. For the human 
proteome it has been estimated that these processes expand the core products of the ~20,000 
ORFs to around 1 million different proteoforms2.
The detection of specific proteoforms has frequently been attempted by antibody-based 
methods3. For this, affinity reagents need to be optimized for each targeted species4. In 
reality, such reagents have frequently been of varying sensitivity and specificity5. 
Alternatively, “top-down” proteomics which uses mass spectrometry to assess intact proteins 
can differentiate individual proteoforms2, but is currently of limited throughput6. Thus, for 
many applications, liquid chromatography-coupled tandem mass spectrometry of 
proteolyzed proteins (LC-MS/MS; “bottom-up” proteomics) has been the method of choice 
for the unbiased, high-throughput identification and quantification of differentially modified 
peptides7,8, even though the information about proteoform association of thus identified 
peptides is lost during the step of enzymatic digestion.
Several “bottom-up” MS technologies have been developed that differ in their performance 
profiles9. They include discovery proteomics employing data-dependent acquisition 
(DDA)10, targeted proteomics by selected or parallel reaction monitoring (SRM11 or 
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PRM12) and data-independent acquisition (DIA)13. DIA methods, exemplified by SWATH-
MS, systematically fragment all precursor ions in a user defined retention time vs. precursor 
ion mass to charge (m/z) window, thus overcoming the stochastic precursor ion selection of 
DDA14. The favorable properties of DIA implemented on high resolution, accurate mass 
instruments include highly consistent detection of analytes across sample cohorts and 
accurate quantification over a dynamic range of more than 4.5 orders of magnitude15, and 
have contributed to the recent popularization of DIA-based methods16.
In bottom-up proteomics, the characterization of proteoforms relies on peptide level 
evidence. In analogy to Smith & Kelleher et al. 2, we herein use the term “peptidoform” to 
describe such specifically modified or mutated peptides with the same backbone amino acid 
sequence. Irrespective of the data acquisition method used, several significant challenges 
remain for peptidoform identification and quantification. They are i) correct identification of 
the peptide backbone sequence, ii) correct identification of the types of modified amino 
acids and, iii) correct localization of the modification(s) within the backbone sequence. 
Modification types have been identified by two different approaches. In the first, modified 
amino acids are included in the database search step as (optional) modification to the peptide 
sequence. In the second, peptide sequences are first identified and subsequently the 
modification mass is inferred from the measured precursor and fragment ion mass shifts to 
the theoretical masses of the unmodified peptide sequences (open or “blind” modification 
search)17. To address the problem of modification site-localization, algorithms have been 
developed which assess site-localization confidence on independent, annotated peptide 
spectrum matches (PSMs) in DDA data18. At a smaller scale, targeted analysis strategies for 
peptidoform assessment were previously used to infer site-localizations and modification 
types in SRM19 or PRM20 data.
In principle, the above methods and strategies could also be applied to the analysis of DIA 
data, either by the spectrum-centric approaches21–24 or by peptide-centric scoring25 based 
targeted data extraction methods as in SWATH-MS14,26. Particularly, the high degree of 
consistency of DIA data is expected to provide additional benefits for site-localization and 
quantification across all runs of a study. However, the structure of DIA methods presents 
additional challenges for peptidoform identification or detection that arise from the large 
precursor isolation windows used for data acquisition14. Specifically, if peptidoform 
precursors differ by modifications for which the m/z increment is below the width of the 
precursor isolation windows used, they are isolated together in the same window. This can 
lead to peak picking conflicts in the retention time (RT) dimension or lead to fragment ion 
interferences when they are co-eluting. For this reason, several studies focusing on peptide 
modifications in complex samples relied on manual inspection of extracted diagnostic 
fragment ions to differentiate peptidoforms27–30 or spectrum-centric assessment of the 
modified peptides22,24,31. However, manual inspection is prone to biases and does not 
scale to dozens or hundreds of samples with tens of thousands of peptides queried per 
sample. Further, the spectrum-centric approaches often have to apply a second peptide-
centric scoring step that is dependent on very specific peptide query parameters31. 
Therefore, there is a critical need for algorithms that can automatically and confidently 
assign peptidoforms to detected peak groups in DIA data sets29.
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Here we present IPF (Inference of PeptidoForms), an algorithm and software tool supporting 
the SWATH-MS14 methodology of data-independent acquisition and targeted data analysis. 
It is configured as a novel component of the OpenSWATH26 workflow supporting the 
analysis of peptidoforms. IPF offers the following features: i) IPF can generate peptide 
query parameters from various sources, such as DDA32 or DIA data, including pseudo 
spectra22 and open modification search results24,31; ii) IPF supports a targeted, hypothesis-
driven approach to assign peptidoforms to candidate peak groups; iii) IPF adopts a multi-tier 
scoring approach, propagating the confidence of detection and site-localization from 
precursors and transitions to peptidoform-level using a Bayesian hierarchical model, and iv) 
IPF integrates seamlessly into the existing workflows to support peptidoform-specific large-
scale experiments.
We benchmarked IPF performance on a “ground truth” sample consisting of a set of 
synthetic phosphopeptides and assessed the applicability, scalability and consistency of 
detection on both, phosphopeptide-enriched and non-enriched samples. We further 
demonstrate the application of the algorithm to a longitudinal heritability study of 
peptidoforms of human blood plasma proteins. The previously acquired data set was derived 
from plasma samples collected at two time points from 36 pairs of monozygotic and 22 pairs 
of dizygotic twins33. The data allowed us to assess the heritability, environmental and 
longitudinal effects on the observed variability of 4532 peptidoforms, and to differentiate 
between inherited and environmentally induced quantitative changes in PTMs.
Results
IPF enables peptidoform characterization from SWATH-MS data sets
The IPF algorithm was developed for the detection of peptidoforms via peptide-centric 
scoring25 of DIA or SWATH-MS data and to support the consistent scoring of distinctive 
peptidoforms across sample cohorts. It extends the scoring systems commonly used for 
unmodified peptides to the peptidoform-level and includes the capability to validate multiple 
concurrent modification types and site-localizations on the same peptide. IPF consists of 
three main components (Fig. 1, Supplementary Notes I.A – I.C):
Step 1: Query parameter generation—Peptide-centric scoring by targeted data 
extraction requires predefined peptide query parameters (also referred to as “Tier 3” 
assays34), consisting of specific transitions (precursor and product ion m/z), normalized 
fragment ion intensities and normalized retention time32. As first step, IPF uses spectral 
libraries or transition lists from prior spectrum-centric analyses of DDA or DIA data, 
processed by database and/or open modification searches as input to constitute sets of 
peptide query parameters. These empirically observed transitions are defined as “detection 
transitions”, because they can be used for the sensitive detection of peptides14. To increase 
specificity and to differentiate peak groups that could originate from closely related peptide 
species, IPF generates theoretical “identification transitions” using a defined model of 
modification residue specificity to probe the candidate peptidoform space, providing 
(weighted) evidence for or against particular peptidoforms (Supplementary Notes I.A, II.A, 
Fig. 1, Supplementary Fig. 1). The output of this step is a set of hybrid peptide query 
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parameters for each peptidoform and precursor charge state, consisting of the different 
transition types, annotated with their specific scoring attributes.
Step 2: Signal processing—Targeted data extraction from the SWATH-MS data and 
peptide-centric scoring using the detection transitions is conducted as established for the 
standard OpenSWATH workflow26. In addition, chromatograms for identification 
transitions of precursor and fragment ions are extracted from MS1 and MS2 maps and 
scored individually against the chromatograms of the detection transitions within the 
boundaries of the detected peak groups (Fig. 1, Supplementary Fig. 1-2). The output of this 
step is the set of scores for candidate peak groups, their identification transition-level 
chromatograms and their precursor signals (Supplementary Notes I.B, II.B-C).
Step 3: Statistical inference and error-rate control—To infer the set of peptidoforms 
at a q-value or false discovery rate (FDR) threshold that is detected in the SWATH-MS data 
set, a statistical inference step is conducted by IPF. This is accomplished by processing the 
scored MS1-, MS2- and transition-level signals by a multi-level, semi-supervised learning 
algorithm, followed by peptidoform inference employing a Bayesian hierarchical model 
(Fig. 1, Supplementary Fig. 1). The confidence scores computed from candidate peak 
groups, precursor ions and individual transition-level chromatograms are propagated towards 
the identification of a peptidoform (Supplementary Notes I.C, II.D-F). The scored peak 
groups can then be used by TRIC35 to propagate the peptidoform-level detection confidence 
across multiple aligned runs to generate a more complete quantitative matrix 
(Supplementary Note II.G).
In summary, IPF extends the standard OpenSWATH workflow by providing confidence 
metrics for unmodified peptide queries as well as for other peptidoforms.
Benchmarking using a synthetic reference data set
To benchmark IPF, we performed SWATH measurements (termed synthetic phosphopeptide 
reference data set) on a collection of 579 heavy isotope labeled, unpurified synthetic 
phosphopeptides corresponding to Saccharomyces cerevisiae proteins involved in a range of 
cellular processes36 (Supplementary Table 1). The synthetic peptides were spiked in a 13-
step dilution series (highest concentration: 0.002 µg/µl, see Methods) into a background 
consisting of an extract of the human cell line HEK-293 to enable assessment of the limits of 
detectability. The maximum dilution reached in the dilution series compared to the synthetic 
peptide mixture without background was 127-fold. Of the full set, 481 peptides were used as 
ground truth for benchmarking, because they were synthesized in only a single site-localized 
peptidoform. However, they contain multiple potentially modifiable residues (on average 
more than 3 modifiable residues, often near the actual modified residue).
We first generated both a comprehensive DDA library of the phosphorylated ground truth 
peptides and a DIA library of the corresponding runs, including background proteome 
(Methods). Peptide query parameters for 297 ground truth peptides were derived from the 
DDA library, which IPF used to extract precursor and fragment ion chromatograms from the 
SWATH-MS data of the phosphopeptide dilution series in the HEK-293 human cell line 
background proteome. Figure 2a depicts the receiver operating characteristic (ROC) curve, 
Rosenberger et al. Page 5
Nat Biotechnol. Author manuscript; available in PMC 2017 December 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
where the cumulative positive (correct site-localizations) and negative detections over all 13 
measurements were used as class labels. False identifications originated from erroneous 
phospho-site localization on correctly detected backbone sequences. At a false positive rate 
of 5%, a recall of 71.6% could be reached. The estimated global false discovery rate (global 
FDR) and local false discovery rate37,38 (local fdr) (Fig. 2b) compared to the ground truth 
indicate that the confidence propagation from transition- to peptidoform-level enabled 
accurate error control in the commonly used ranges of 1-5% fdr/FDR, with a small 
underestimation of the error in the higher ranges. Detectability at a global FDR of 5% over 
the whole dilution series shows a linear relationship of peptidoform detectability confidence 
to the abundance, with 195 correctly detected peptidoforms in the sample with the highest 
peptide concentration (Fig. 2c). In direct comparison to OpenSWATH, IPF produces a 
reduction of false site localizations by 87.0%, while recovering 85.4% of the true 
OpenSWATH signals at 5% estimated FDR. Quantification of correctly detected 
peptidoforms over the dilution series normalized to the undiluted sample indicates accurate 
quantification until the 1:15 dilution step, with a slight overestimation of the abundance in 
the more diluted samples (Fig. 2d). Confidence on the peptidoform-level in general requires 
slightly more intense signals than on the peptide sequence-level, indicating that the lowered 
sensitivity of IPF compared to OpenSWATH originates from ambiguous lower intensity 
signals (Fig. 2e). Supplementary Figure 3 depicts the equivalent results using a DIA library 
generated by DIA-Umpire22, where IPF achieved similar relative performance metrics 
compared to the DDA library, but due to the lower size of the input library, the absolute 
number of detected peptidoforms was smaller.
We further used the results of the DIA-Umpire analysis to benchmark the site-localization 
component of IPF against established methods for spectrum-centric site-localization 
(Supplementary Note III.B, Supplementary Fig. 4). LuciPHOr39,40 is a recently developed 
algorithm for site localization. In addition to site-localization it also estimates the false 
localization rate (FLR). Using a version of IPF reduced to the second, site-localization layer 
of the Bayesian hierarchical model we analyzed the synthetic phosphopeptide reference data 
set to compare the correct and wrong site-localized peptides at estimated false localization 
rates with DIA-Umpire/LuciPHOr. IPF provided more sensitive results with a recovery of 
66.7% of all true site-localized peptides at 5% false positive rate, compared to 55.3% as 
achieved by DIA-Umpire/LuciPHOr.
The above results demonstrate that IPF accurately determines peptidoforms with 
modification site-localization using spectral libraries generated both by DDA- and DIA-
based methods. IPF reaches a favorable tradeoff between sensitivity and selectivity 
compared to the standard peptide-centric workflows, for example implemented in 
OpenSWATH.
Benchmarking using a data set generated from phosphopeptide-enriched samples
To assess the scalability of IPF for the analysis of thousands of peptides, we generated a data 
set of phosphopeptide-enriched samples of human U2OS cells. Cells were either treated with 
nocodazole or left untreated (control) and the resulting patterns were comparatively analyzed 
by IPF. Nocodazole arrests cells at the mitotic stage and thus has a substantial effect on 
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signaling pathways involving phosphorylation41. We acquired ten biological replicates, 
processed in parallel, each for nocodazole-treated and control samples, both in DDA and 
DIA modes (see Methods). We then used the DDA data to generate a spectral library for 
quantitative analysis by IPF on the corresponding 20 DIA runs covering 4,298 
phosphopeptides (Methods, Supplementary Notes IV.B)
We next analyzed the quantitative data matrix produced by IPF across all ten replicates of 
each condition, considering only peak groups with at least one confident detection or 
quantification per biological condition (Fig. 3). For the nocodazole treated and the control 
samples, IPF achieved both consistent detection and quantification for 62.6% (nocodazole) 
and 47.5% (control) of all phosphopeptides (Fig. 3a-b). To investigate the effect that 
consistency of quantification has in dependency of the number of replicates, we conducted 
differential expression analysis using mapDIA42 on variable numbers of sampled replicates. 
Depending on the number of replicates, more than 400 differentially expressed peak groups 
were detected (Fig. 3c, significance thresholds: FDR < 0.01 & log2(FC) > 2). Considering 
only three replicates, IPF identified 134 significant peak groups. These results demonstrate 
that IPF can achieve consistent detection and quantification for enriched phosphopeptide 
data sets across multiple samples.
Analysis of phosphopeptide-enriched samples is a frequent objective of discovery 
proteomics workflows. The performance of IPF should thus be assessed in comparison to the 
state-of-the-art; however, comparing algorithms based on different concepts and requiring 
different input data (DDA vs. DIA) is challenging (Supplementary Notes IV.A). Using the 
DDA and DIA data of the phosphopeptide-enriched samples described above and non-
enriched samples of a previously published 14-3-3 scaffold protein interactome study43, we 
conducted assessments of a DDA-based workflow and IPF (Supplementary Notes IV.B-C, 
Supplementary Fig. 5-6). The results suggest that within the parameter space tested, IPF 
using DIA data substantially improves the consistency of detection and quantification of 
phosphopeptides compared to DDA-based workflows.
Assessment of variance components of peptidoform abundance in human blood plasma
To demonstrate the utility of IPF for biological research requiring larger cohort sizes, we 
applied it to a longitudinal twin study consisting of 116 individuals (58 twin pairs), who 
donated blood plasma twice within a time span of 2-7 years. The study was designed to 
assess the effects of heritability and environment on blood plasma protein abundance33. We 
revisited the previously acquired data set of this large sample cohort to investigate the 
biological variability of 10 selected post-translational modifications (oxidation, deamidation, 
carbamylation, formylation, acetylation, methylation, carboxylation, ubiquitination, 
nitrosylation, phosphorylation) that were previously associated with blood plasma 
proteins44–48. The samples further contained 73 spiked-in stable isotope labelled (SIS) 
peptides, corresponding to 37 plasma proteins33,49, with levels generally adjusted to the 
endogenous peptides in the human plasma proteome49. The two isotope labels for arginine 
and lysine and static carbamidomethylation modification were added to the list of included 
modification types.
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As a first step we generated a spectral library by searching DDA data from chromatographic 
fractions of a pooled sample. This library was used for the analysis of the 232 samples of the 
twin study (plus 10 technical and whole-process replicates) by IPF. Figure 4a depicts the 
spectral library and IPF cumulative and average detection statistics. In summary, of the 
9,272 peptidoforms covered by the library, 7653 (82.5%) could be detected by IPF 
cumulatively across all samples with an average of 3153.7 (34.0%) per run. Of all the 
peptidoforms, 49.9% were unmodified, 48.5% carried PTMs of likely artefactual origin and 
5.5% were modified due to likely biological causes (Methods, Supplementary Table 2). 
Importantly, peptidoforms can carry both artefactual and biological PTMs.
Different peptidoforms and modification types can be differentially expressed between 
samples and conditions based on sample-specific biochemical reactions, protein abundance 
and other effects. While in general, modified peptidoforms are expressed over a similar 
range than unmodified peptidoforms (Supplementary Note V.A, Supplementary Fig. 7-8), 
abundance differences can be of the on/off type or quantitatively different between 
individuals. Accordingly, Figure 4b depicts the distribution of the observed detectability (in 
number of samples) grouped according to modification type. The spiked-in SIS peptides 
could be detected consistently across almost all the twin samples. In contrast, the median 
detectability of endogenous unmodified and modified peptides was more variable across the 
data set, ranging from ~50 – 100 samples, suggesting significant variability of peptidoform-
level abundance in undepleted blood plasma samples. We assessed the quantitative variation 
of the peptidoforms across the samples (Fig. 4c): Technical and whole-process replicates 
indicate a median coefficient of variation (CV) of <10% and <20%, respectively 
(Supplementary Fig. 9-10) 26. In contrast, peptides subject to biological variation, showed a 
median CV of 30 – 50%. Our data thus provides a complex snapshot of the peptidoforms of 
blood plasma proteins in a human cohort.
To understand the root causes, i.e. heritable, common and individual environmental and 
longitudinal effects of biological variation of endogenous human plasma peptidoforms, we 
utilized a linear mixed model approach to fit our data after imputation of background 
intensities (Methods). Queried peptidoforms were only considered if they were detected in at 
least 20 samples of the data set, resulting in 4532 peptidoforms targeted by 5829 queried 
peptides. Of these, 1755 peptidoforms (1954 peptide queries, e.g. different precursors and 
site-localizations contained within the library) contained at least one significant (q-value < 
1%) component that could be ascribed to the factors generating biological variance, 
specifically heritability, familial environment, individual environment and the 2-7 year 
longitudinal visits (Fig. 4d, Supplementary Table 3, Supplementary Data 1). Among all 
peptide queries, the longitudinal component (variance between two longitudinal visits of the 
same individual33) cumulatively was found to be the major component contributing to the 
biological variability (h2w: 15.3%), followed by heritability (h2r: 12.0%), the individual 
environmental (h2id: 8.2%), and the common environmental effects (c2: 7.8%), with the 
unexplained effects accounting for 56.7% on average. These results are consistent with the 
original study on the protein level33, where the average component effects were of similar 
magnitude (h2w: 13.5%, h2r: 13.6%, h2id: 11.6%, c2: 10.8%, e2: 50.5%).
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We further investigated the effects of the quantitative peptidoform variability on selected key 
blood plasma proteins in more detail. Human serum albumin (ALBU), the major protein 
constituent accounting for 55% of the plasma protein mass50, was represented by 440 
peptidoforms (9.7%), whereas all the other plasma proteins were covered by 11.6 
peptidoforms on average (Supplementary Table 4). In general, the individual peptidoforms 
were similarly affected by the different root causes of observed variability as compared to 
other proteins, suggesting that peptidoform diversity was mainly depending on the general 
ALBU protein abundance level in plasma (Supplementary Note V.C, Supplementary Fig. 
11-12). Further, to demonstrate the heritable or familial environmental components of 
different peptidoforms that can be efficiently dissected using the data, we investigated allele 
variants of ApoE, a protein associated with the high-density lipoprotein (HDL) class. We 
confirmed that its main biological effects can be mainly attributed to the familial 
environmental components (Supplementary Note V.D, Supplementary Fig. 13).
ApoA1 and other members of the high density lipoprotein (HDL) complex have previously 
been found to be affected by oxidative modifications introduced by myeloperoxidase 
(MPO)51,52. Oxidative modifications at specific sites, particularly oxTrp7252, were found 
to inhibit the cholesterol acceptor function of ApoA1, resulting in a dysfunctional protein 
that is associated with atherosclerosis and cardiovascular disease52. In this context, we 
investigated the heritable and environmental effects on oxidative modifications on ApoA1 
within the twin cohort. In total, the variance components of 12 oxidized (4 tryptophan, 7 
methionine, 1 tryptophan + methionine) peptidoforms could be decomposed in the data set, 
that were constituted of 3 tryptophan and 4 methionine sites from different regions of the 
protein structure53. We found oxTrp72 among the oxidized tryptophan peptidoforms, along 
with two other known sites52 in close proximity (Fig. 5a), oxTrp50 and oxTrp108, and 
found that their peptidoform abundance levels are longitudinally upregulated with a relative 
variance contribution of 19.8–29.7% (Fig. 5b, Supplementary Fig. 13). While also the 
abundances of other peptidoforms, including the unmodified ones, are longitudinally 
upregulated, the longitudinal regulation is different for peptidoforms having oxidized 
methionine residues. Two previously oxidized methionine residues, hypothetical biomarkers 
for atherosclerosis54, oxMet86 and oxMet112, were detected and quantified in our data as 
well. In contrast to the constant or upregulated oxidized tryptophan peptidoforms (Fig. 5b, 
Supplementary Fig. 14), their peptidoform abundance levels show an inverse longitudinal 
effect that could also be explained to be technical artifacts: The samples of the first visit 
were stored for a longer period of time and thus contained higher fractions of spontaneous 
methionine oxidations. These data thus support the hypothesis that oxTrp50 and oxTrp108, 
in contrast to the potential technical artefacts oxMet86 and oxMet112, are biochemically 
induced by MPO under a similar mechanism as oxTrp72 and might be useful as candidate 
biomarkers for proatherogenic processes52. Intriguingly, IPF successfully dissected the 
differential technical and biological variation of oxMet112 and oxTrp108, which was 
measured by two isobaric peptidoforms of the same peptide backbone sequence.
Discussion
Peptidoforms carrying biologically relevant post-translational modifications are often more 
difficult to measure consistently across many samples because their abundance is frequently 
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more variable than the abundance of dominating other peptidoforms, e.g. the non-modified 
peptide. Targeted data extraction was demonstrated to improve the consistency of peptide 
detection and quantification, particularly for large-scale DIA analysis22,26. Although the 
DIA analysis of peptidoforms can provide excellent quantitative performance, the medium- 
to large- precursor-isolation window configurations can result in the co-isolation of different 
peptidoforms22,55, making their discrimination very challenging, particularly in cases 
where the peptidoforms differ by site-localization.
Peptide-centric scoring using peptide query parameters is very sensitive but is frequently not 
selective enough for targeting peptidoforms. IPF improves the selectivity by integrating 
evidence on different levels to a single peptidoform confidence for each peak group. It is 
thus conceptually related to spectrum-centric site-localization applicable to DIA data, e.g. 
DIA-Umpire22,56/LuciPHOr39,40 or SWATHProphetPTM31, but with a focus on consistent 
detection and quantification. This is useful for TRIC35, which transfers the detection 
confidence across different runs based on the retention times and detection confidence of the 
candidate peak groups. If in a certain fraction of measurements, the peptidoform detection is 
less confident because of bad or missing precursor signals or missing site-determining 
transition-level chromatograms, TRIC can recover some of these signals. The seamless 
integration of IPF with TRIC confidently extends the list of peptidoforms detected and 
quantified in individual measurements to a quantitative matrix over large sample cohorts.
The functions performed by IPF are important for large-scale, complex data sets, as 
demonstrated by the peptidoform-level analysis of the twin plasma data set. Despite of its 
promise for clinical applications, blood plasma presents one of the most analytically 
challenging human-derived proteomes, due to its different tissue proteome subsets and the 
large dynamic range with only 22 proteins accounting for ~99% of the total protein 
mass50,57. IPF enabled us to study the heritable and environmental components of 
peptidoforms carrying different types of PTMs. We found that most peptidoforms are 
expectedly co-regulated with the generating proteins; however, our approach enables further 
discrimination of the effects on peptidoform-level into biological and technical causes, as 
exemplified by ApoA1 oxidation.
In conclusion, we describe, benchmark and apply a new algorithm for targeted data analysis 
of DIA data sets that is geared towards the consistent detection and quantification of 
peptidoforms based on low- to high-confidence spectral libraries from supporting hypothesis 
generating workflows based on DDA and DIA. Our generic approach is scalable to hundreds 
of samples, optimizing for peptidoform-level selectivity while maintaining high sensitivity. 
The validation based on the synthetic phosphopeptide reference data set established the 
accurate error-rate control capabilities of IPF. The application to a data set generated from 
enriched phosphopeptide samples proved the general applicability and improvements of IPF 
for commonly employed experimental designs, such as phosphoproteomic profiling. Further, 
the application to the challenging twin blood plasma data set demonstrates the utility for 
practical applications in complex samples. We expect that the availability of the algorithm in 
the open source workflow OpenSWATH, the generic utility for all modification types and 
scalability will enable confident quantification of PTMs in large-scale studies using DIA 
data.
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Online Methods
Synthetic phosphopeptide reference data set
Sample preparation
Crude synthetic peptides: To generate the synthetic phosphopeptide reference data, a set of 
579 synthetic, unpurified, heavy-isotope labeled phosphopeptides (Thermo Scientific 
Biopolymers) was used. These phosphopeptides represent biologically relevant sequences 
from S. cerevisiae proteins, and include previously published markers of cellular 
processes36. The complete peptide set contains a mixture of singly and doubly 
phosphorylated sequences with in average more than 3 modifiable residues per peptide 
(serines, threonines or tyrosines, often near each other). The complete sequence list can be 
found in Supplementary Table 1. All peptides were mixed with equal volumes and the 
concentrations were estimated to be around 0.002 µg/µl based on the vendor estimates of the 
unpurified peptides. The resulting peptide mix was either analyzed directly in DDA mode 
for spectral library generation or spiked into a human cell line background proteome in a 13-
step dilution series and analyzed in SWATH mode for the generation of the synthetic 
phosphopeptide reference data set (see below).
Human cell line background proteome: HEK-293 cell pellets were lysed on ice by using a 
lysis buffer containing 8 M urea (EuroBio), 40 mM Tris-base (Sigma-Aldrich), 10 mM DTT 
(AppliChem) and complete protease inhibitor cocktail (Roche). The resulted mixtures were 
sonicated in 4 °C for 5 mins using a VialTweeter device (Hielscher-Ultrasound Technology) 
with full power and centrifuged at 21,130 g, 4 °C for 1 h to remove the insoluble material. 
The supernatant protein mixtures were transferred and the protein amount was determined 
with a Bradford assay (Bio-Rad). Aliquots of 2 mg protein mixtures were reduced by 5 
tris(carboxyethyl)phosphine (Sigma-Aldrich) and alkylated by 30 mM iodoacetamide 
(Sigma-Aldrich). Then 5 volumes of precooled precipitation solution containing 50% 
acetone, 50% ethanol, and 0.1% acetic acid were added to the protein mixture and kept at 
-20 °C overnight. The mixture was centrifuged at 20,400 g for 40 min. The pellets were 
further washed with 100% acetone and 70% ethanol with centrifugation at 20,400 g for 40 
min. The samples were then resolved by 100mM NH4HCO3 and were digested with 
sequencing-grade porcine trypsin (Promega) at a protease/protein ratio of 1:50 overnight at 
37 °C58. Digests were combined and purified with Sep-Pak C18 Vac Cartridge (Waters). 
Peptide amount was determined by using Nanodrop ND-1000 (Thermo Scientific). An 
aliquot of retention time calibration peptides from the iRT-Kit (Biognosys) was spiked into 
the total mixture of the sample at a ratio of 1:20 (v/v) to correct relative retention times 
between runs59.
Dilution series of synthetic peptides: The heavy-labeled synthetic phosphopeptide mix 
described above was spiked in 13 defined dilution steps into a HEK293 total cellular 
proteome background (final constant background concentration in all 13 dilution samples = 
0.5 µg/µl). The 13 dilution steps of the heavy-labeled synthetic phosphopeptides were: 0, 
1:1, 1:3, 1:4, 1:7, 1:9, 1:15, 1:19, 1:31, 1:39, 1:63, 1:79 and 1:127. This dilution range was 
judged to be appropriate because at the final lowest concentration step the phosphopeptide 
Rosenberger et al. Page 11
Nat Biotechnol. Author manuscript; available in PMC 2017 December 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
amounts loaded onto the column were approximately estimated to be in the range of tens of 
attomoles.
DDA mass spectrometry—The synthetic phosphopeptide mix (without added 
background added) was measured on a SCIEX 5600+ TripleTOF mass spectrometer 
operated in DDA mode in technical triplicates. The mass spectrometer was interfaced with 
an Eksigent NanoLC Ultra 2D Plus HPLC system as previously described14,43,60. Peptides 
were directly injected onto a 20-cm PicoFrit emitter (New Objective, self-packed to 20 cm 
with Magic C18 AQ 3-μm 200-Å material), and then separated using a 120-min gradient 
from 2–35% (buffer A 0.1% (v/v) formic acid, 2% (v/v) acetonitrile, buffer B 0.1% (v/v) 
formic acid, 90% (v/v) acetonitrile) at a flow rate of 300 nL/min. MS1 spectra were 
collected in the range 360–1,460 m/z for 500 ms. The 20 most intense precursors with 
charge state 2–5 which exceeded 250 counts per second were selected for fragmentation, and 
MS2 spectra were collected in the range 50–2,000 m/z for 150 ms. The precursor ions were 
dynamically excluded from reselection for 20 s. Acquired file names:
Type Filename
Replicate 1 chludwig_K141203_001_IDA
Replicate 2 chludwig_K141203_002_IDA
Replicate 3 chludwig_K141203_003_IDA
DIA mass spectrometry—The 13-step dilution series of the synthetic heavy 
phosphopeptide mix (spiked into a constant human background) was measured in SWATH-
MS mode on the same LC-MS/MS systems used for DDA measurements in technical 
triplicates14,43,60. In SWATH-MS mode the SCIEX 5600+ TripleTOF instrument was 
specifically tuned to optimize the quadrupole settings for the selection of 64 variable wide 
precursor ion selection windows. The 64-variable window schema was optimized based on a 
normal human cell lysate sample, covering the precursor mass range of 400–1,200 m/z. The 
effective isolation windows can be considered as being 399.5~408.2, 407.2~415.8, 
414.8~422.7, 421.7~429.7, 428.7~437.3, 436.3~444.8, 443.8~451.7, 450.7~458.7, 
457.7~466.7, 465.7~473.4, 472.4~478.3, 477.3~485.4, 484.4~491.2, 490.2~497.7, 
496.7~504.3, 503.3~511.2, 510.2~518.2, 517.2~525.3, 524.3~533.3, 532.3~540.3, 
539.3~546.8, 545.8~554.5, 553.5~561.8, 560.8~568.3, 567.3~575.7, 574.7~582.3, 
581.3~588.8, 587.8~595.8, 594.8~601.8, 600.8~608.9, 607.9~616.9, 615.9~624.8, 
623.8~632.2, 631.2~640.8, 639.8~647.9, 646.9~654.8, 653.8~661.5, 660.5~670.3, 
669.3~678.8, 677.8~687.8, 686.8~696.9, 695.9~706.9, 705.9~715.9, 714.9~726.2, 
725.2~737.4, 736.4~746.6, 745.6~757.5, 756.5~767.9, 766.9~779.5, 778.5~792.9, 
791.9~807, 806~820, 819~834.2, 833.2~849.4, 848.4~866, 865~884.4, 883.4~899.9, 
898.9~919, 918~942.1, 941.1~971.6, 970.6~1006, 1005~1053, 1052~1110.6, 
1109.6~1200.5 (including 1 m/z window overlapping). SWATH MS2 spectra were collected 
from 50 to 2,000 m/z. The collision energy (CE) was optimized for each window according 
to the calculation for a charge 2+ ion centered upon the window with a spread of 15 eV. An 
accumulation time (dwell time) of 50 ms was used for all fragment-ion scans in high-
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sensitivity mode and for each SWATH-MS cycle a survey scan in high-resolution mode was 
also acquired for 250 ms, resulting in a duty cycle of ~3.45 s. Per MS injection 2 µg of 
protein amount (i.e., 4µL of the final dilution mixture) was loaded onto the HPLC column. 
Acquired file names:
Dilution (PSGS) Filename
Dilution 1:0 chludwig_K150309_013_SW
Dilution 1:1 chludwig_K150309_012_SW
Dilution 1:3 chludwig_K150309_010_SW
Dilution 1:4 chludwig_K150309_011_SW
Dilution 1:7 chludwig_K150309_008_SW
Dilution 1:9 chludwig_K150309_009_SW
Dilution 1:15 chludwig_K150309_006b_SW
Dilution 1:19 chludwig_K150309_007b_SW
Dilution 1:31 chludwig_K150309_004b_SW
Dilution 1:39 chludwig_K150309_005b_SW
Dilution 1:63 chludwig_K150309_002b_SW
Dilution 1:79 chludwig_K150309_003b_SW
Dilution 1:127 chludwig_K150309_001b_SW
Spectral library and peptide query parameter generation—We generated a peptide 
sequence and precursor-specific (1% peptide sequence FDR) spectral library for the 
phosphorylated peptides. Peptide-centric scoring of DIA data benefits from using saturated, 
optimized spectral libraries that best cover the target peptides26. For this reason, we 
searched the 45 DDA runs of the original study36 and acquired three new replicate DDA 
runs of a pooled sample of the synthetic library without background proteome (see above). 
Then, consensus spectra for different site-localized peptidoforms were generated from the 
search output. To increase the coverage, the peptide identifications were not post-processed 
by a site-localization algorithm. This resulted in over-annotation of the peptides potentially 
contained in the sample because spectra originating from the same peptidoform could be 
assigned to different (incorrect) site-localizations. The library was used to derive sets of 
peptide query parameters for 554 peptidoforms (e.g. PEPT(Phospho)IDEK), mapping to 297 
combinations of peptide sequences and numbers of phosphorylated residues (e.g. 
PEPTIDEK + 1 phosphorylation). In parallel, to assess the application of IPF on spectral 
libraries generated directly from DIA data, a second library was generated by DIA-
Umpire22 using the 13-step dilution series DIA data, which includes a HEK-293 proteome 
background. The thus generated library contained peptide query parameters for 169 
peptidoforms, mapping to 122 combinations of peptide sequences and numbers of 
phosphorylated residues (Methods, Supplementary Fig. 3).
DDA database search and spectral library generation—All original36 and new raw 
instrument data acquired in DDA mode were centroided and converted to mzXML using 
qtofpeakpicker (ProteoWizard61 3.0.10200) as described previously32. The phosphopeptide 
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sequences were appended with a set of contaminant proteins, iRT peptide sequences and 
pseudo-reverse decoys. The files were searched using Comet62 (2015.02) using the default 
parameters for high mass accuracy instruments: peptide mass tolerance: 20 ppm 
(monoisotopic), isotope error enabled, fully tryptic digestion with max 5 missed cleavages, 
static C (Carbamidomethyl), variable M (Oxidation), variable K (Label:13C(6)15N(2)), 
variable R(Label:13C(6)15N(4)), variable STY (Phospho), max variable mods: 5. 
PeptideProphet38,63 (TPP64 5.0.0) with parameters -dDECOY_ -OAPdlIwt was run on all 
search results together and iProphet65 was used to combine all results. SpectraST66 (TPP 
5.0.0) was used to generate a spectral library of all peptide identifications at iProphet FDR 
1% with the following parameters: -cP0.8326 -c_IRR -c_IRTirtkit.txt -cICID-QTOF -
c_RDYDECOY -cAC –cM. All peptides except the synthetic phosphopeptides were 
excluded from the library. OpenMS67 (OpenMS 2.1) was used for all following steps: 
ConvertTSVToTraML was used to convert the SpectraST MRM file to a TraML. 
OpenSwathAssayGenerator was applied on the TraML with following parameters: -
swath_windows_file swath64.txt -allowed_fragment_charges 1,2,3,4 -
enable_ms1_uis_scoring -max_num_alternative_localizations 2000-
enable_identification_specific_losses -enable_identification_ms2_precursors. 
OpenSwathDecoyGenerator was applied to append decoys to the target peptide query 
parameters using the following parameters: -method shuffle -append -mz_threshold 0.1 -
remove_unannotated. All OpenMS tools were executed using the modified chemistry 
parameters for phosphorylation (OpenMS.phospho.params) (ProteomeXchange repository).
DIA database search and spectral library generation—All raw instrument data 
acquired in DIA mode were centroided and converted using the SCIEX MS Data Converter 
(Beta Version 1.3) and msconvert (ProteoWizard61 3.0.7162) using the parameters as 
suggested22. The signal extraction module of DIA-Umpire22 (1.2, 2014.10) was applied to 
the 13-step dilution series SWATH-MS data set using recommended parameters. The ORF 
protein translation FASTA database for yeast was obtained from the Saccharomyces 
Genome Database68 (2015-02-24) and appended with the non-redundant reviewed human 
protein FASTA obtained from the UniProtKB/Swiss-Prot69 (2015-02-23) and the iRT 
peptide sequences and pseudo-reverse decoys. The files were searched using Comet62 
(2015.02) using the parameters recommended for DIA-Umpire22: peptide mass tolerance: 
40 ppm (monoisotopic), isotope error enabled, fully tryptic digestion with max 2 missed 
cleavages, static C (Carbamidomethyl), variable M (Oxidation), variable K (Label:
13C(6)15N(2)), variable R(Label:13C(6)15N(4)), variable STY (Phospho), max variable 
mods: 5. PeptideProphet38,63 (TPP64 4.8.0) with parameters -dDECOY_ -OAPdlIwt was 
run independently per file and iProphet65 was used to combine all quality tier Q1 & Q3 (Q2 
were excluded) results. SpectraST66 (TPP 4.8.0) was used to generate a spectral library of 
all peptide identifications at iProphet FDR 1% with the following parameters: -cP0.7850 -
c_IRR -c_IRTirtkit.txt -cICID-QTOF -c_RDYDECOY -cAC –cM. OpenMS (https://
github.com/grosenberger/OpenMS/tree/feature/ipf @7924fc3) was used for all following 
steps: ConvertTSVToTraML was used to convert the SpectraST MRM file to a TraML. 
OpenSwathAssayGenerator was applied on the TraML with following parameters: -
swath_windows_file swath64.txt -allowed_fragment_charges 1,2,3,4 -
enable_ms1_uis_scoring -max_num_alternative_localizations 20 -
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enable_identification_specific_losses -enable_identification_ms2_precursors. 
OpenSwathDecoyGenerator was applied to append decoys to the target peptide query 
parameters using the following parameters: -method shuffle -append -mz_threshold 0.1 -
remove_unannotated. All OpenMS tools were executed using the modified chemistry 
parameters for phosphorylation (OpenMS.phospho.params) (ProteomeXchange repository).
OpenSWATH and PyProphet—OpenSwathWorkflow (OpenMS 2.1) was run with the 
following parameters -min_upper_edge_dist 1 -mz_extraction_window 0.05 -
rt_extraction_window 600 -extra_rt_extraction_window 100 -min_rsq 0.95 -min_coverage 
0.6 -use_ms1_traces -enable_uis_scoring -Scoring:uis_threshold_peak_area 0 -
Scoring:uis_threshold_sn -1 -Scoring: stop_report_after_feature 5 -tr_irt 
hroest_DIA_iRT.TraML. The following subset of scores was used on MS2-level: 
xx_swath_prelim_score library_corr yseries_score xcorr_coelution_weighted 
massdev_score norm_rt_score library_rmsd bseries_score intensity_score xcorr_coelution 
log_sn_score isotope_overlap_score massdev_score_weighted xcorr_shape_weighted 
isotope_correlation_score xcorr_shape. All MS1 and UIS scores were used for PyProphet.
PyProphet (https://github.com/grosenberger/pyprophet/tree/feature/ipf @93ec307) was run 
on a concatenated file of all 13 runs containing only the unambiguous phosphopeptides with 
the following parameters:
--final_statistics.emp_p --qvality.enable --qvality.generalized
--ms1_scoring.enable --uis_scoring.enable
--semi_supervised_learner.num_iter=20 --xeval.num_iter=20
--ignore.invalid_score_columns.
PyProphet in site-localization mode only (https://github.com/grosenberger/pyprophet/tree/
feature/ipf_flr @b92ccf9) was run on a concatenated file of all 13 runs with the following 
parameters:
--final_statistics.emp_p --qvality.enable --qvality.generalized
--ms1_scoring.enable --uis_scoring.enable
--semi_supervised_learner.num_iter=20 --xeval.num_iter=20
--ignore.invalid_score_columns --uis_scoring.disable_precursor_inference.
LuciPHOr—LuciPHOr39,40 2 (1.2014Oct10-iprophet) was modified to support iProphet65 
posterior probabilities, required for DIA-Umpire pseudo spectra identifications. Static, 
variable and target residue modifiability was defined as for the database search and neutral 
losses for phosphorylation were allowed as suggested. The fragment ion tolerance was set to 
0.025 Da and the algorithm was run in CID mode. All other parameters were set as 
suggested by the default settings.
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Validation using the synthetic phosphopeptide reference data set—To validate 
the IPF results on the synthetic phosphopeptide reference data set, the synthesized reference 
peptide sequences were used as ground truth. To specifically assess the global and local false 
discovery rates, only those detected peak groups were used where the unmodified peptide 
sequence, modification types (except variable methionine oxidation) and modification 
numbers matched the synthesized peptides exactly. If multiple peptide queries resulted in 
peak groups for the same peptidoform (or equal site-localization), i.e. when multiple 
precursors could be detected, only the best scoring one would be used. All perfect matches 
to the ground truth were counted as true, all others as false positives.
Statistics and visualization—Visualization of Fig. 2 and Supplementary Fig. 3 was 
conducted using the boxplot function of the R package “graphics” with the default 
parameters: The box borders represent the 25th and 75th quantile, respectively. The bold bar 
represents the 50th quantile. The whiskers are defined as following: upper whisker: 
min(max(x), Q_3 + 1.5*IQR); lower whisker: max(min(x), Q_1-1.5*IQR), with Q_1 and 
Q_3 representing the 25th and 75th quantile, respectively, and IQR representing the inter-
quantile range Q_3-Q_1.
Data set generated from phosphopeptide-enriched samples
Sample preparation
Phospho-enrichment of human cell line and sample preparation: U2OS cells were 
grown in DMEM media (Life Technologies) supplemented with 10% FCS (BioConcept), 
1% penicillin-streptomycin (Life Technologies). Cells cultures (approximately 3-4 million 
cells per plate) were treated with nocodazole (Sigma-Aldrich) at a final concentration of 
100ng/ml for 18 hours. Treated and untreated samples (ten replicates respectively) were 
collected, washed with PBS and frozen in liquid nitrogen. To include variation of the sample 
preparation, we directly processed all the cells from each plate for the protein digestion (see 
above) and phosphoproteomic analysis. Phosphopeptide enrichment was performed from 
approximately 1mg of total peptide mass according to a modified protocol70 using TiO2 
resin (GL Sciences). In short, the dried peptides were dissolved in a loading buffer (80% 
ACN, 5% TFA, 1M glycolic acid) and vortexed in a shaker for 10 min at 25°C, 1400 rpm. 
Peptide mixtures were added to equilibrated enrichment resin preloaded in a 200ul tip with a 
C8 plug (3M Empore). The resin was then washed once with the loading buffer, once with 
80% ACN, 0.1% TFA, and once with 50% ACN, 0.1% TFA. The peptides were eluted with 
a 0.6 M NH4OH solution (Sigma-Aldrich), followed by an elution from the C8 plug with 
50% ACN, 0.1% FA. The pH of the eluates was adjusted to <3 and the phosphopeptide 
samples were desalted using C18 ultramicrospin columns (Nest). Samples were re-
suspended as described above. Phosphopeptide mixture originating from ~10% of the 
starting cell materials was injected for shotgun and SWATH measurements.
DDA mass spectrometry—The samples were measured on a SCIEX 6600 TripleTOF 
mass spectrometer operated in DDA mode in ten replicates for each experimental condition. 
The samples were measured as described above with a modified LC gradient of 2-30% 
buffer during the same acquisition time. Acquired file names:
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Treatment Replicate Filename
Control 1 yanliu_I170114_001_PhosCyc1_shotgun
2 yanliu_I170114_005_PhosCyc2_shotgun
3 yanliu_I170114_009_PhosCyc3_shotgun
4 yanliu_I170114_013_PhosCyc4_shotgun
5 yanliu_I170114_017_PhosCyc5_shotgun
6 yanliu_I170114_021_PhosCyc6_shotgun
7 yanliu_I170114_025_PhosCyc7_shotgun
8 yanliu_I170114_029_PhosCyc8_shotgun
9 yanliu_I170114_033_PhosCyc9_shotgun
10 yanliu_I170114_037_PhosCyc10_shotgun
Nocodazole 1 yanliu_I170114_002_PhosNoco1_shotgun
2 yanliu_I170114_007_PhosNoco2_shotgun
3 yanliu_I170114_011_PhosNoco3_shotgun
4 yanliu_I170114_015_PhosNoco4_shotgun
5 yanliu_I170114_019_PhosNoco5_shotgun
6 yanliu_I170114_023_PhosNoco6_shotgun
7 yanliu_I170114_027_PhosNoco7_shotgun
8 yanliu_I170114_031_PhosNoco8_shotgun
9 yanliu_I170114_035_PhosNoco9_shotgun
0 yanliu_I170114_039_PhosNoco10_shotgun
DIA mass spectrometry—The samples were measured in SWATH-MS mode as 
described above on the same LC-MS/MS system used for DDA measurements in ten 
replicates for each experimental condition with the following difference: The MS1 
acquisition time for each cycle was set to 200ms and the MS2 scan range was set to 
300-2000 m/z. Acquired file names:
Treatment Replicate Filename
Control 1 yanliu_I170114_003_PhosCyc1_SW
2 yanliu_I170114_006_PhosCyc2_SW
3 yanliu_I170114_010_PhosCyc3_SW
4 yanliu_I170114_014_PhosCyc4_SW
5 yanliu_I170114_018_PhosCyc5_SW
6 yanliu_I170114_022_PhosCyc6_SW
7 yanliu_I170114_026_PhosCyc7_SW
8 yanliu_I170114_041_PhosCyc8_SW_rep
9 yanliu_I170114_034_PhosCyc9_SW
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Treatment Replicate Filename
10 yanliu_I170114_038_PhosCyc10_SW
Nocodazole 1 yanliu_I170114_004_PhosNoco1_SW
2 yanliu_I170114_008_PhosNoco2_SW
3 yanliu_I170114_012_PhosNoco3_SW
4 yanliu_I170114_016_PhosNoco4_SW
5 yanliu_I170114_020_PhosNoco5_SW
6 yanliu_I170114_024_PhosNoco6_SW
7 yanliu_I170114_028_PhosNoco7_SW
8 yanliu_I170114_032_PhosNoco8_SW
9 yanliu_I170114_036_PhosNoco9_SW
10 yanliu_I170114_040_PhosNoco10_SW
Spectral library and peptide query parameter generation—The MaxQuant 
workflow71 provides integrated site-localization of the phosphopeptides and MS1 precursor-
level label-free quantification by alignment and matching between runs and can thus 
generate a quantitative matrix at the level of phosphopeptides for DDA data sets. In total, 
MaxQuant identified 10,051 unique peptide sequences carrying phosphorylated residues, 
filtered at 1% PSM FDR for the whole data set, in at least one of the ten replicates of each 
experimental condition. From these results, we generated a library covering a subset of 
8,013 phosphorylated unique peptide sequences for the analysis of the corresponding 20 
DIA runs using IPF, because not all PSMs fulfilled the criteria for peptide queries (e.g. at 
least six annotated fragment ions).
MaxQuant analysis and spectral library generation—All raw data was analyzed in 
a combined setting with MaxQuant (1.5.6.5) using primarily the default parameters71: The 
non-redundant reviewed human protein FASTA was obtained from the UniProtKB/Swiss-
Prot69 (2016-12-19) and appended with iRT peptide sequences and searched with static C 
(Carbamidomethyl), variable M (Oxidation) and variable STY (Phospho) modifications. 
“Match-between-runs” and the MaxLFQ algorithm were enabled. All specific parameters 
are provided in the file mqpar.xml in the ProteomeXchange repository.
To derive peptide query parameters, we selected the best scoring spectrum per peptidoform 
as reported by Andromeda in the file “msms.txt”. RT calibration was conducted using the 
spiked-in iRT-kit per run. OpenSwathAssayGenerator and OpenSwathDecoyGenerator 
(OpenMS 2.1) were run as described above. For all other analyses, we used the reported 
confidence values and intensities from the file “Phospho (STY)Sites.txt”.
OpenSWATH, PyProphet and TRIC—OpenSwathWorkflow (OpenMS 2.1) and 
PyProphet (https://github.com/grosenberger/pyprophet/tree/feature/ipf @93ec307) were 
used as described above.
TRIC (msproteomicstools/master @d2b5e17) was run with the following parameters:
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feature_alignment.py: --file_format openswath --fdr_cutoff 0.01 --max_fdr_quality 0.2 --
mst:useRTCorrection True --mst:Stdev_multiplier 3.0 --method LocalMST --max_rt_diff 30 
--alignment_score 0.0001 --frac_selected 0 --realign_method lowess_cython --
disable_isotopic_grouping
Statistics and visualization—The site-localization and peptidoform FDR for MaxQuant 
and IPF were computed for phosphopeptides only as described in Supplementary Notes II.F.
Visualization of Fig. 3 and Supplementary Fig. 5 was conducted using the heatmap.2 
function of the R package “gplots” with the default parameters, but sorted by generation of a 
dendrogram on the row-level only. The intersection of peptides containing phosphorylated 
residues between IPF and MaxQuant was used for all comparisons. For the quantification 
heatmaps, the dendrograms were applied from the corresponding heatmaps for 
identification/detection.
Fig. 3c and Supplementary Fig. 5c depict only peak groups / peptide precursors reported as 
differentially expressed by mapDIA (significance thresholds: FDR < 0.01 & log2(FC) > 2). 
mapDIA42 (3.0.1) was used with the following parameters:
LEVEL=1, EXPERIMENTAL_DESIGN=IndependentDesign, NORMALIZATION=tis, 
MIN_OBS=1, MIN_DE=.01, MAX_DE=.99.
Analysis of the 14-3-3β data set
Spectral library and peptide query parameter generation—The 18 DDA runs were 
supplemented with 2 phosphopeptide-enriched DDA runs to enable mapping of potentially 
unidentified MS1 features of the biologically-relevant samples with identified MS/MS 
spectra from the two enriched runs. Of all confidently identified peptides (PSM FDR: 1%), 
MaxQuant cumulatively identified 1,286 unique phosphorylated peptide sequences, of which 
we could generate a spectral library for 1,068 peptides that was used for the analysis of the 
corresponding 18 DIA runs by IPF.
MS data analysis—The analysis of the 14-3-3β data set43 was conducted identically as 
for the enriched phosphopeptide data set. Normalization was conducted using the aLFQ 
(https://github.com/grosenberger/aLFQ/tree/develop @94dfd2b) function 
normalizeBetweenRuns against the peptides of the 14-3-3β bait protein.
Statistics and visualization—The site-localization and peptidoform FDR for MaxQuant 
and IPF were computed for phosphopeptides only as described in Supplementary Notes II.F.
mapDIA42 (3.0.1) was used with the following parameters:
Phosphopeptide-level: Level=1, EXPERIMENTAL_DESIGN=ReplicateDesign, 
MIN_OBS=1, MIN_DE=.01, MAX_DE=.99
Protein-level: Level=2, EXPERIMENTAL_DESIGN=ReplicateDesign, SDF=2, 
MIN_CORREL=0.2, MIN_OBS=1, MIN_PEP_PER_PROT=1, MAX_PEP_PER_PROT=5, 
MIN_DE=.01, MAX_DE=.99
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The 14-3-3β binding motifs computed as part of the original study43 were used to map 
motifs to phosphopeptides. Visualization of Supplementary Fig. 6b-c was conducted using 
the boxplot function of the R package “graphics” with the default parameters as described 
above.
Assessment of variance components of post-translational modifications in human blood 
plasma
Spectral library and peptide query parameter generation—We generated a 
spectral library by searching DDA data from strong anion exchange chromatography 
fractions of trypsinized, depleted plasma samples. The searches were carried out separately 
for each type of modification. This resulted in a cumulative library covering 467 non-
redundant proteins, 6,928 peptide sequences and 9,272 peptidoforms at 0.2% iProphet65 
peptide FDR, consistent with the proteome coverage of the original study33. Of all the 
peptidoforms, 49.9% were unmodified and 33.5% contained carbamidomethylated residues. 
The other modification types were respectively present at the level of 0 – 9.9% of the 
detected peptides (Fig. 4a). Based on residue specificity (see below), we conservatively 
grouped PTMs (preferring artefactual causes) to originate from artefactual or biological 
effects. 4,495 peptidoforms contain PTMs that are likely technical artefacts, whereas 511 are 
attributed with biological effects (Supplementary Table 2).
DDA database search and spectral library generation—All raw instrument data 
acquired in DDA mode were centroided and converted to mzXML using msconvert 
(ProteoWizard61 3.0.7162). The non-redundant reviewed human protein FASTA was 
obtained from the UniProtKB/Swiss-Prot69 (2015-02-23) and appended with iRT peptide 
sequences and pseudo-reverse decoys. In addition, a second FASTA was generated based on 
the first with additional sequence variants of the human ApoE protein (ProteomeXchange 
repository). The files were searched using Comet62 (2015.02) using the default parameters 
for high mass accuracy instruments: peptide mass tolerance: 20 ppm (monoisotopic), isotope 
error enabled, fully tryptic digestion with max 2 missed cleavages, static C 
(Carbamidomethyl), variable M (Oxidation), max variable mods: 5. Based on these 
parameters, for each additional variable modification type, a separate search was conducted: 
MW (Oxidation), c (Amidated), NQ (Deamidated), Kn (Carbamyl), K (Label:
13C(6)15N(2)), R (Label:13C(6)15N(4)), KnST (Formyl), EK (Carboxy), Kn (Acetyl), Y 
(Nitro), KRDEc (Methyl), STY (Phospho), Y (Sulfo), K (GG), KR (Dimethyl), ApoE. 
PeptideProphet38,63 (TPP64 4.8.0) with parameters -dDECOY_ -OAPdlIwt was run 
independently per file and iProphet65 was used to combine all results. The heavy isotope 
labeled forms of K and R were included because heavy peptide standards with established 
SRM methods49 were spiked in the plasma digest for SWATH-MS quantification. 
Specifically, these heavy peptide standards included 73 spiked-in SIS peptides, 
corresponding to 37 plasma proteins33,49, with levels generally adjusted to the endogenous 
peptides in the human plasma proteome49. Furthermore, Amidation, sulfonation and 
dimethylation were excluded at later stages of the analysis, because they did either not 
generate enough suitable detection transitions (amidation), were either not identified with 
confidence (sulfonation; potential conflict with phosphorylation due to very similar mass 
and residue specificity), or resulted in only one detected peptide (dimethylation). 
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SpectraST66 (TPP/SVN r7019, custom build with disabled hardcoded modifications) was 
used to generate a spectral library of all peptide identifications at iProphet FDR 0.2% with 
the following parameters: -cP0.9 -c_IRR -c_IRTirtkit.txt -cICID-QTOF -c_RDYDECOY -
cAC –cM. OpenMS version (https://github.com/grosenberger/OpenMS/tree/feature/ipf 
@7924fc3) was used for all following steps: ConvertTSVToTraML was used to convert the 
SpectraST MRM file to a TraML. OpenSwathAssayGenerator was applied on the TraML 
with following parameters: -swath_windows_file swath32.txt -allowed_fragment_charges 
1,2,3,4 -enable_ms1_uis_scoring -max_num_alternative_localizations 20 -
enable_identification_specific_losses -enable_identification_ms2_precursors. 
OpenSwathDecoyGenerator was applied to append decoys to the target peptide query 
parameters using the following parameters: -method shuffle -append -mz_threshold 0.1 -
remove_unannotated. All OpenMS tools were executed using the modified chemistry 
parameters for the extended modification set (OpenMS.extended.params) 
(ProteomeXchange repository).
OpenSWATH, PyProphet and TRIC—Peptide queries based on the spectral library were 
run using IPF against the SWATH-MS data set consisting of 232 samples (with additional 
replicates, see Methods). To improve the consistency of the quantitative matrix, the inter-run 
alignment algorithm TRIC35 was applied based on the peptidoform-level confidence 
estimates of IPF to transfer the confidence to aligned peak groups and to impute background 
noise values (Methods). Based on the detected peak groups for all runs, this increased the 
matrix consistency (all peak groups vs all runs) by 10.3%. Cumulatively, 82.5% of the 
peptidoforms present in the library could be detected in at least one sample and 50.3% were 
detected in at least 20 samples with a run-specific IPF peptide query FDR threshold at 1% 
(Supplementary Table 2). This recovery rate corresponds well with expectations in cases in 
which SWATH-MS data from undepleted and unfractionated plasma digest is queried with a 
sample-specific library generated from multiple fractions of the same sample 26.
All steps were applied to the complete data set consisting of the 232 samples and 
additionally the 6 technical and 4 whole process replicates and 4 repeat runs.
OpenSwathWorkflow (https://github.com/grosenberger/OpenMS/tree/feature/ipf @7924fc3) 
was run with the following parameters -min_upper_edge_dist 1 -mz_extraction_window 
0.05 -rt_extraction_window 600 -extra_rt_extraction_window 100 -min_rsq 0.95 -
min_coverage 0.6 -use_ms1_traces -enable_uis_scoring -Scoring:uis_threshold_peak_area 0 
-Scoring:uis_threshold_sn -1 -Scoring: stop_report_after_feature 5 -tr_irt 
hroest_DIA_iRT.TraML. The following subset of scores was used on MS2-level: 
xx_swath_prelim_score library_corr yseries_score xcorr_coelution_weighted 
massdev_score norm_rt_score library_rmsd bseries_score intensity_score xcorr_coelution 
log_sn_score isotope_overlap_score massdev_score_weighted xcorr_shape_weighted 
isotope_correlation_score xcorr_shape. All MS1 and UIS scores were used for PyProphet.
PyProphet (https://github.com/grosenberger/pyprophet/tree/feature/ipf @93ec307) was run 
on all runs independently with the following parameters:
--final_statistics.emp_p --qvality.enable --qvality.generalized
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--ms1_scoring.enable --uis_scoring.enable --uis_scoring.expand_peptidoforms
--xeval.num_iter=10 --ignore.invalid_score_columns.
TRIC (msproteomicstools/master@d2b5e17) was run with the following parameters:
feature_alignment.py: --file_format openswath --fdr_cutoff 0.01 --max_fdr_quality 0.2 --
mst:useRTCorrection True --mst:Stdev_multiplier 3.0 --method LocalMST --max_rt_diff 30 
--alignment_score 0.0001 --frac_selected 0 --realign_method lowess_cython --
disable_isotopic_grouping
requantAlignedValues.py: --disable_isotopic_grouping --disable_isotopic_transfer --
realign_runs lowess_cython --method singleShortestPath --do_single_run
Residue modifiability and differentiation between artefactual and biological 
PTMs—Differentiation between biological and artefactual causes is challenging for most 
modification types, because many can originate from both causes, depending on the residue 
and context. However, to provide an approximate assessment, we generated a manually 
refined list of UniMod residue modifiability:
Artefactual PTMs: C (Carbamidomethyl), Kn (Carbamyl), K (Carboxy), NQ (Deamidated), 
KST (Formyl), K (Label:13C(6)15N(2)), R (Label:13C(6)15N(4)), DE (Methyl), MW 
(Oxidation), c (Methyl)
Biological PTMs: Kn (Acetyl), E (Carboxy), KR (Dimethyl), K (GG), KR (Methyl), Y 
(Nitro), STY (Phospho), Y (Sulfo), n (Formyl)
Variance decomposition of peptidoform level—Quantitative variance decomposition 
on peptide query / peptidoform level was conducted as previously reported33 with 
normalization of the peptidoform intensities by a rank normal transformation per run. The 
input data was restricted to ensure that each peptidoform could be detected in at least 20 
samples below the threshold (1% IPF peptide query peptidoform FDR). The heritability 
analysis was conducted using SOLAR72 (7.6.4). The significance of the components was 
computed by assuming a X2 distribution of  and one degree of freedom. Correction 
for multiple testing was conducted using Storey’s q-value73.
Statistics and visualization—Visualization of Fig. 4, 5b and Supplementary Fig. 9, 10, 
12 and 14 was conducted using the boxplot function of the R package “graphics” or 
“ggplot2” as described above. Fig. 5b and Supplementary Fig. 12 and 14 indicate outliers as 
dots. The coefficient of variation (CV) values visualized in Fig. 4b and Supplementary Fig. 
9, 10 were computed using the cv function of the R package “raster”. Only CV values where 
peptidoforms were detected in at least 2 samples were considered, all others were omitted.
Supplementary Fig. 11 indicates the quantitative variability of each peptidoform as mean 
with the error bars indicating the standard deviation.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. IPF analysis workflow overview.
Step 1: Query parameter generation: Based on a spectrum-centric workflow (DDA or DIA), 
peptide query parameters consisting of detection (most intense) and identification (site 
determining) transitions for all peptidoforms are generated. Step 2: Signal processing: Using 
a multi-tier scoring approach, the detection and identification transition-level and precursor 
ion chromatograms are extracted from the SWATH maps. The chromatograms on detection 
transition-level are used to find candidate peak groups against which the chromatograms of 
the precursor ion and identification transitions are scored. The multi-tier scoring estimates 
the posterior probability (PP) for the candidate peak groups using the detection transitions. 
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In the step on precursor and transition-level, the PPs are estimated for the likelihood that 
individual precursor ions or identification transition-level chromatograms are originating 
from the peak group associated peptide. Step 3: Statistical inference: A Bayesian 
hierarchical model (BHM) integrates the precursor and transition PPs, according to residue 
specificity, to peptidoform PPs. In addition to the peptidoforms, the PP that the signal is a 
false positive is being updated.
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Figure 2. Benchmarking on the synthetic phosphopeptide reference data set.
Spiked-in synthetic yeast phosphopeptides36 were measured in a 13-step dilution series with 
a human cell line background. IPF was applied using a spectral library generated from DDA 
measurements of the synthetic peptides. a) The receiver operating characteristic (ROC) 
indicates high sensitivity at commonly used confidence thresholds with 71.6% recovery at 
5% (grey dotted line) false positive rate. b) The estimated global false discovery rate (FDR) 
or q-values are plotted against the true FDR, computed using the ground truth. The dashed 
diagonal line indicates the optimum. The estimated local false discovery rate (fdr) or 
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posterior error probability (PEP) is plotted against the actual fdr, approximated using the 
ground truth with a window size of 50037. IPF enables accurate estimation in the commonly 
used ranges of 1-5% fdr/FDR, with a small underestimation of the error in the higher ranges. 
c) The dilution series of synthetic spiked-in standard peptides against the constant human 
cell line digest and the detected true (green) and false (red) peptidoforms at 5% FDR are 
depicted. The light colors (OSW; OpenSWATH) represent the detectable peptide sequence-
specific peptide query-level candidate peak group signals. The dark colors (IPF) represent 
the corrected, peptidoform-specific signals. A high gain in selectivity with a slight drop in 
sensitivity can be observed for IPF in comparison to OpenSWATH. d) The quantification of 
the peak groups (normalized against the 1:0 sample) is compared against the ground truth 
(red line). Until dilution step 1:15 the quantification is accurate, with a slight bias for 
overestimation at lower abundance dilution steps. The numbers above the boxplots indicate 
the number of peptides per dilution steps that are also present in the 1:0 step. e) The 
boxplots depict the intensities of correct peptidoforms and background (BG) peptides at 5% 
FDR. To achieve high confidence on peptidoform-level, IPF requires slightly higher signal 
intensities than OpenSWATH on peptide-level. Supplementary Figure 3 depicts the same 
plots for a library generated using DIA-Umpire.
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Figure 3. Benchmarking using a data set generated from phosphopeptide-enriched samples.
Enriched phosphopeptide samples of a human U2OS cell line treated with nocodazole and 
without treatment (control) were measured in both DDA and DIA modes in each 10 
replicates. a) 200 peptides were randomly selected and the corresponding detected peak 
groups and peptide precursors are visualized in a heatmap (sorted by a hierarchical 
dendrogram for identification/detection by rows) for detection confidence (blue) and 
quantification (red-yellow; including alignment). IPF achieved a high level of completeness 
for both detection and quantification in individual experimental conditions (Nocodazole 
N01-N10: 62.6%; Controls C01-C10: 47.5%). b) The consistency of quantification for all 
intersecting peptides is depicted. c) Differential expression analysis was conducted using 
mapDIA (significance thresholds: FDR < 0.01 & log2(FC) > 2). For IPF on both MS2 peak 
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group (IPF-MS2) and MS1 (IPF-MS1) precursor levels, the same peptide/precursor-level 
model and parameters were used.
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Figure 4. Assessment of variance components of peptidoform abundance in human blood 
plasma.
a) The overlaid histogram of unmodified and modified peptides grouped according to 
modification type contained in the spectral library, confidently detected in at least one 
sample (shaded grey) and the average number of detected peptidoforms per sample (shaded 
black). b) The detectability in number of samples of peptidoforms grouped by modification 
types indicates a median detectability in ~50-100 samples. c) The coefficient of variation 
(CV; computed only if the peptidoform was detected in at least 2 runs) of the quantile 
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normalized peak group intensities across different modification types is depicted. Technical 
and whole-process variability are consistently lower than the intensities of unmodified and 
modified peptides across the cohort, indicating that biological variance constitutes a major 
component of the total variance. d) The cumulative relative variance contributions (RVC) of 
the heritable (h2r), common environment (c2), individual environment (h2id) and 
longitudinal (h2w) effects per peptidoform peak group grouped and ordered by effect type 
and contribution are depicted.
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Figure 5. Oxidative tryptophan modifications of ApoA1.
a) The asymmetric units form an antiparallel four-helix bundle in an elliptical ring shape53. 
The myeloperoxidase (MPO) binding site is highlighted in yellow. On the opposite site, 
oxTrp72 (h2w (longitudinal): 19.8%, h2id (individual environment): 18.3%, h2r (heritable): 
17.5%, c2 (common environment): 0%, e2 (unexplained): 44.4%), a potential biomarker for 
dysfunctional ApoA1 is highlighted in red. oxTrp50 (green; h2w: 29.7%, h2r: 13.2%, h2id: 
6.8%, c2: 0%, e2: 50.3%) and oxTrp108 (blue; h2w: 29.7 %, c2: 13.5%, h2id: 8.9%, h2r: 
0%, e2: 47.9%) are in close spatial proximity to oxTrp72. For all three modification sites, 
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the longitudinal effect is the major component. b) The boxplots depict the peptidoform 
abundance fold changes between timepoints 2 (later) and 1 (log2(NI_2/NI_1); NI: quantile 
normalized intensity) for all individuals. oxTrp50 (green) and oxTrp72 (red) are stable in 
abundance over both time points with a slight increase in intensity, which is also present for 
the other related peptidoforms. The oxTrp108 (blue) peptidoforms show the largest increase 
in abundance when comparing the second to the first visit. However, the methionine 
oxidized peptidoforms (oxMet112) show a decrease, which might be induced by the longer 
time of sample storage and thus spontaneous methionine oxidation for the samples at the 
first visits. For all sites the unmodified peptidoforms also show a longitudinal increase, 
indicating a longitudinally increasing total protein abundance.
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